President Trump is looking to take swift action to bring down prices on groceries and prescription drugs, the White House announced this week.

The President is planning to bank wins achieved through his tough stance to-date on tariffs, which has opened overseas markets to US goods. Now, Trump plans to leverage an opening to roll back tariffs where he is satisfied that American concerns have been met.

The news will be welcomed by Republicans who reportedly have been growing worried about grocery and pharmaceutical prices ahead of the 2026 midterms.

Last week, Axios reported that behind closed doors, some DC Republican consultants had been growing concerned about losing voters over the issue of inflation.

One anonymous GOP operative was quoted saying, “We don’t want Democrats making campaign ads about $8 Lucky Charms and grandma unable to get prescription drugs because of shortages.”

Axios further reported that of particular concern to “GOP insiders and lawmakers”, is “the cost of drugs and consumer items.”

Recent polls have shown inflation is still a top issue for voters, with Trump looking to seize on momentum and his popular mandate to further deliver on campaign promises driving down costs.

This will put Trump and Republicans even more on offense against the pharmaceutical industry, which has recently been ired by HHS Secretary Robert F Kennedy Jr’s assaults on their high profits and perceived self-dealing including in the realm of vaccines, and which has recently been amping up attacks on a key drug discount program that disproportionately benefits red, rural, working class areas where Trump’s support is high.

Gutting that program is now a top three issue for Big Pharma, and they have been looking to win over hearts and minds with the Chamber of Commerce class with a new ad that American Greatness sources say recently ran on CNBC and Fox Business within the DC area.

One GOP consultant told American Greatness that ad, which focuses on a character named “Mark,” appeared aimed at cultivating more goodwill with Virginia Gov. Glenn Youngkin, who is reportedly laying the groundwork to run for President in 2028 and sided with Big Pharma on a key bill focused on the drug discount program in question.

The GOP consultant queried the optics of seeking to dismantle a drug discount program in view of Trump’s current focus on achieving more drug discounts, not fewer.

The Real Clear Politics polling average shows that Trump is somewhat more popular at this stage of his current presidency than he was at the same point in his first term, so the alignment against the Pharma industry and in support of his base voters seems to be working for him, politically.